BAA FY26C1CP41: ROBUST CLINICAL ENDPOINT BIOEQUIVALENCE STUDIES USING MODEL INTEGRATED EVALUATION APPROACHES
$499,922
| Recipient | UPPSALA UNIVERSITET UEI KTRDK57SR316 |
|---|---|
| Award ID | 75F40126C00097 |
| Award amount | $499,922 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — Food and Drug Administration |
| NAICS | 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| PSC | AJ11 |
| Set-aside | Unrestricted |
| Start date | Sep 1, 2026 |
| End date | Aug 31, 2028 |
| Place of performance | — |
| Record updated | Sep 28, 2026 |
View the official award record
More awards won by UPPSALA UNIVERSITET
MODEL-INTEGRATED STRATEGIES FOR BIOEQUIVALENCE EVALUATION OF DRUGS WITH HIGH VARIABILITY AND/OR LONG HALF-LIFE
Department of Health and Human Services · $265,368 · Sep 26, 2022
Our catalog shows awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. $0 today for 14 days (card required), then $49.99/month.
Search open bids